文献速递乳腺癌

肿瘤浸润淋巴细胞与激素受体阳性/HER2阴性乳腺癌复发评分的关系:四项前瞻性研究的分析

Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
PubMed 文献 · Eur J Cancer · 2023-10-26

本研究纳入四项多中心前瞻性研究中T1-T3、N0-N1且具有复发评分(RS)和肿瘤浸润淋巴细胞(TILs)数据的激素受体阳性/HER2阴性乳腺癌患者811例,分析RS与TILs的相关性。结果显示连续TILs与RS呈显著弱正相关(Pearson系数=0.223,p<0.001),中/高TIL水平肿瘤在高低RS亚组中显著富集(p=0.006)。作者提出将RS与TILs组合的免疫基因组模型可能有助于免疫治疗策略中的患者选择。

要点

  • 连续TILs与RS呈显著弱正相关(Pearson系数=0.223,p<0.001)。
  • 中/高TIL水平肿瘤显著富集于高RS亚组(p=0.006),Luminal A和Luminal B亚组中均得到证实。
  • 高RS患者中,Luminal A有16.7%、Luminal B有26.7%的肿瘤具有中/高TILs。

核心结论

  • RS与TILs仅捕获激素受体阳性/HER2阴性肿瘤微环境生物学中轻微重叠的信息。
  • 作者证明将RS与TILs组合成复合免疫基因组模型是可行的,该模型可能有助于在Luminal样疾病免疫治疗策略的进一步开发中指导和聚焦患者选择。

研究设计与样本

  • 研究纳入四项多中心前瞻性研究中T1-T3、N0-N1且具有RS®和TILs数据的乳腺癌患者,共811例。
  • RS®和TILs作为连续变量和分类变量分析;RS®分类为0-10(低风险)、11-25(中风险)、26-100(高风险);TILs分类为低TILs(0-10%)、中TILs(11-59%)、高TILs(60-100%)。

主要发现

  • RS分布(n=810):低风险22.0%,中风险61.2%,高风险16.8%。
  • TIL分布(n=455):低TILs 84.6%,中TILs 13.6%,高TILs 1.8%。
  • 连续TILs与RS呈显著弱正相关(Pearson系数=0.223,p<0.001)。
  • 中/高TIL水平肿瘤显著富集于高RS亚组(p=0.006),Luminal A和Luminal B队列中均得到证实。
  • 高RS患者中,Luminal A有16.7%、Luminal B有26.7%的肿瘤具有中/高TILs。

临床怎么用

  • 作者提出将RS与TILs组合成复合免疫基因组模型,可能有助于在Luminal样疾病免疫治疗策略的进一步开发中指导和聚焦患者选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical value of tumor infiltrating lymphocytes (TILs) in hormone receptor-positive (HR+)/HER2- breast cancer (BC) may be unearthed by focusing on more biologically aggressive tumors. Here we deepen and describe the correlation between RS and TILs, proposing an immuno-genomic model for HR+ /HER2- BC. METHODS: We enrolled T1-T3, N0-N1 BC patients with available RS® and TILs in the context of four multicenter, prospective studies. RS® and TILs were considered as continuous and categorical variables. RS® was categorized into: 0-10 (low risk), 11-25 (intermediate risk) and 26-100 (high risk); TILs were categorized into: low TILs (0-10%), intermediate TILs (11-59%) and high TILs (60-100%). RESULTS: 811 patients were included. RS distribution was (n = 810): low risk 22.0%, intermediate risk 61.2%, high risk 16.8%. TIL distribution was (n = 455): low TILs 84.6%, intermediate TILs 13.6% and high TILs 1.8%. A significant, weak positive, linear correlation was found between continuous TILs and RS (Pearson coefficient=0.223, p < 0.001). When considering RS and TILs categories, tumors with intermediate/high TIL levels significantly enriched the high RS subgroup (p = 0.006). This was confirmed both within Luminal A and Luminal B cohorts. Among high-RS patients, 16.7% of Luminal A and 26.7% of Luminal B tumors had intermediate/high TILs. CONCLUSIONS: We observed that RS® and TILs capture only slightly overlapping information on the biology of HR+ /HER2- tumor microenvironment. We demonstrated the feasibility of combining RS and TILs into a composite immuno-genomic model, which may serve the purpose of guiding and focalizing patient selection in the further development of immunotherapy strategies for Luminal-like disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Miglietta F, Dieci MV, Giarratano T, et al. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies. Eur J Cancer. 2023. PMID: 37950941. doi:10.1016/j.ejca.2023.113399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。